Astellas Pharma Inc. (TYO: 4503)
Japan
· Delayed Price · Currency is JPY | Market Cap | 3.25T |
| Revenue (ttm) | 1.70T |
| Net Income (ttm) | 21.52B |
| Shares Out | 1.79B |
| EPS (ttm) | 11.96 |
| PE Ratio | 151.75 |
| Forward PE | 94.62 |
| Dividend | 74.00 (4.11%) |
| Ex-Dividend Date | Sep 27, 2024 |
| Volume | 4,246,500 |
| Open | 1,788.00 |
| Previous Close | 1,801.00 |
| Day's Range | 1,772.50 - 1,820.00 |
| 52-Week Range | 1,426.00 - 2,238.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2024 |
About Astellas Pharma
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAG... [Read more]
Financial Performance
In 2023, Astellas Pharma's revenue was 1.60 trillion, an increase of 5.60% compared to the previous year's 1.52 trillion. Earnings were 17.05 billion, a decrease of -82.73%.
Financial StatementsNews
Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
The Astellas Life Sciences Center hosts the company's first U.S.-based open innovation SakuLab™ incubator space dedicated to fostering pioneering science through collaboration with external partners T...
Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
- Pooled analyses from two SKYLIGHT™ studies highlight impact on sleep disturbance and impairment, relationship between improvements in the frequency or severity of hot flashes and mood - Pooled data ...
Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
- Pooled analyses from two SKYLIGHT™ studies highlight impact on sleep disturbance and impairment, relationship between improvements in the frequency or severity of hot flashes and mood - Pooled data ...
European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer
- First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years1 - European Marketing Authorization base...
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
- HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therap...
China confirms charges laid against Japanese citizen accused of spying
Accused not identified but Astellas Pharma says one of its Japanese employees has been indicted by Chinese authorities.
Japan's Astellas says employee indicted by China's prosecutors
Chinese authorities have indicted a Japanese employee of Astellas Pharma Inc , who had been detained in China since March 2023 on suspicion of espionage, the Japanese pharmaceutical company said on We...
UK regulator approves Astellas' gastric cancer drug
Britain's health regulator said on Wednesday it has approved Astellas Pharma's drug to treat a type of gastric cancer.
Astellas Pharma Inc. (ALPMF) Q1 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q1 2024 Earnings Conference Call August 1, 2024 3:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IRO Tadaaki Taniguchi - CMO Claus Zieler -...
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
- If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union - A decision on the EU marketing authorizat...
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care for...
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy
- Collaborative Research on Innovative Cartilage Organoid Cell Therapy for Intervertebral Disc Degenerative Disease using Astellas' Universal Donor Cell Technology - TOKYO and OSAKA, Japan , July 22, ...
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction cancers as the first and only CLDN18.2-targeted therapy in ...
Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies
- Focuses on digitizing cell manufacturing processes through robotics technology TOKYO , May 21, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") tod...
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
- 154,000 square-foot lab and office facility creates a central location for Astellas' West Coast cell and gene therapy research and business development operations TOKYO and SAN FRANCISCO , May 8, 2...
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors - TOKYO and SAN DIEGO , May 1, 2024 /PRNewswire/ -- Astellas Pharma In...
Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2023 Results Conference Call April 25, 2024 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and Investor Relations Officer Naoki Okamura - ...
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI...
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
- Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy- - If approved, enfortumab ...
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Permanent J-code J2782 effective April 1, 2024 NORTHBROOK, Ill. , March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announ...
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
VYLOY approved in combination with chemotherapy for patients with human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer MHLW a...
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
- If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient populations in...
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
DUNDEE, Scotland--(BUSINESS WIRE)--Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unme...
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
TOKYO , March 3, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of the first patient in the STARLIGHT™ 2 Phase 3 pivotal stu...
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
- Innovative universal, off-the-shelf in vivo CAR-T Cell therapy - TOKYO and BOSTON , Feb. 15, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and K...